Rege Nephro Co., Ltd.
4:00 PM - 4:15 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104A
Rege Nephro is pre-clinical stage company developing a allogenic cell therapy by human iPS cell-derived nephron progenitor cells (iNPCs) for chronic kidney disease (CKD). iNPCs are differentiated from iPS cells and originally created by Dr. Osafune, a professor of CiRA, Center for iPS Cell Research and Application, Kyoto University. iNPCs are effective for the treatment of pre-clinical CKD models when injected into the kidney. The manufacturing process has been established and the therapy is currently undergoing pre-clinical studies. We are aiming to begin clinical trials in the coming year.
Another pipeline is a small molecule drug for ADPKD, discovered from a disease model reconstituted from patient-derived iPS cells invented from Osafune Lab. Currently, a Phase II clinical trial is planned in this year.
Rege Nephro has been funded by top-tier Japanese venture capital firms and is now seeking business partners for these pipelines and new investors.
Another pipeline is a small molecule drug for ADPKD, discovered from a disease model reconstituted from patient-derived iPS cells invented from Osafune Lab. Currently, a Phase II clinical trial is planned in this year.
Rege Nephro has been funded by top-tier Japanese venture capital firms and is now seeking business partners for these pipelines and new investors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2019
Main Therapeutic Focus:
Regenerative Medicine
Lead Product in Development:
iPS cell-derived nephron progenitor cells
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
